-

Shareholder Alert: Robbins LLP is Investigating GoodRx Holdings, Inc. (GDRX) on Behalf of Shareholders

SAN DIEGO & SANTA MONICA, Calif.--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP is investigating GoodRx Holdings, Inc. (NASDAQ: GDRX) on behalf of shareholders to determine whether certain GoodRx officers and directors violated the Securities Exchange Act of 1934 and breached their fiduciary duties to the Company. GoodRx is a holding company that owns and operates a U.S. consumer-focused digital healthcare platform.

If you suffered a loss due to GoodRx Holdings, Inc.'s misconduct, click here.

GoodRx Holdings, Inc. (GDRX) Misled Shareholders Regarding its Business Prospects

According to a class action complaint filed against GoodRx, Defendants timed the Company's initial public offering ("IPO") to happen just before Amazon.com, Inc. announced its online pharmaceutical business that would compete with GoodRx, which maximized the amount of money the selling stockholders could raise in the IPO and artificially inflated GoodRx's stock price.

GoodRx closed its IPO on September 25, 2020, selling 39.8 million shares for $33 per share, generating over $1.3 billion in gross offering proceeds. In its Registration Statement, GoodRx touted its successes in growing market share and stated that it is "a market leader with a significant scale and brand advantage over our competitors. Our growth accelerates self-reinforcing network effects that further strengthen our competitive position." However, at the time these statements were made, defendants knew that Amazon was about to enter the online prescription medication ordering and fulfillment business because of the Company's close relationship with Amazon and reliance on Amazon Web Services to support the Company's platform. On November 17, 2020, Amazon announced two new pharmacy offerings, which would compete directly with GoodRx's platform. On this news, GoodRx's stock declined 23%, erasing more than $4 billion of the Company's market capitalization.

GoodRx Holdings, Inc. (GDRX) shareholders have legal options. All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:
Lauren Levi
(800) 350-6003
llevi@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. To be notified if a class action against GoodRx Holdings, Inc. settles or to receive free alerts about companies engaged in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Lauren Levi
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
llevi@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Investor Notice: Robbins LLP Informs Investors of the SES AI Corporation Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired SES AI Corporation (NYSE: SES) securities between January 29, 2025 and March 4, 2026. SES claims to be a "leading developer and manufacturer of high-performance, AI-enhanced Lithium-Metal (“Li-Metal”) and Lithium-ion (“Li-ion”) rechargeable battery technologies and battery materials for Energy Storage Systems (“ESS”), Urban Air Mobility (“UAM”)...

Investor Notice: Robbins LLP Informs Investors of the Regencell Bioscience Holdings Limited Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Regencell Bioscience Holdings Limited (NASDAQ: RGC) securities between October 28, 2024 and October 31, 2025. Regencell is a purported early-stage bioscience company focused on the research, development, and commercialization of traditional Chinese medicine (“TCM”) for the treatment of attention-deficit/hyperactivity disorder (“ADHD”) and autis...

Investor Notice: Robbins LLP Informs Investors of the Globant S.A. Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Globant S.A. (NYSE: GLOB) common stock between February 15, 2024 and August 14, 2025. Globant is a Luxembourg-incorporated international technology company that provides digital consulting and related services. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LL...
Back to Newsroom